Previous 10 | Next 10 |
EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that manage...
Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation 4D-150 PRISM randomized Phase 2 Dose Expansion Cohort (N=51) 24-week encore results to be presented in a poster EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics...
2024-05-01 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-29 06:36:20 ET Summary 4D Molecular Therapeutics is a biotechnology company that develops genetic medicines using its Therapeutic Vector Evolution platform. The company's pipeline includes promising ophthalmology, pulmonology, and cardiology candidates, with Phase 3 progre...
2024-04-15 12:22:22 ET "We consider the cystic fibrosis and Fabry programs as free options and that validation of additional pipeline assets could provide long- term upside potential," she added. 4D-710, currently in phase 1/2, is the cystic fibrosis candidate, while 4D-310, also in phase 1...
2024-04-15 06:00:04 ET Gena Wang from Barclays issued a price target of $45.00 for FDMT on 2024-04-15 03:43:00. The adjusted price target was set to $45.00. At the time of the announcement, FDMT was trading at $26.35. The overall price target consensus is at $45.40 with ...
2024-04-15 05:30:02 ET Barclays analyst issues OVERWEIGHT recommendation for FDMT on April 15, 2024 03:43AM ET. FDMT was trading at $26.35 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy recommend...
2024-04-01 09:15:05 ET Jefferies analyst issues BUY recommendation for FDMT on April 1, 2024 07:51AM ET. The previous analyst recommendation was Buy. FDMT was trading at $31.86 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...
2024-03-28 15:15:05 ET BMO Capital analyst issues OUTPERFORM recommendation for FDMT on March 28, 2024 01:31PM ET. The previous analyst recommendation was Outperform. FDMT was trading at $31.06 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-03-28 10:43:38 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm 4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024 Goldman reinstates buy rating on 4D Molecular, cites upcoming catalysts ...
News, Short Squeeze, Breakout and More Instantly...
4D Molecular Therapeutics Inc. Company Name:
FDMT Stock Symbol:
NASDAQ Market:
4D Molecular Therapeutics Inc. Website:
NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 4D Molecular Therapeutics, Inc. ("4D Molecular" or "the Company") (NASDAQ:FDMT). Investors who purchased 4D Molecular securities are encouraged to obtai...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
Robust reduction in anti-VEGF injection treatment burden through Week 24 achieved in 30 patients at planned Phase 3 dose (3E10 vg/eye) with 89% reduction in annualized injection rate; 93% of patients received 0 or 1 injection and 77% were injection-free Improvement in mean best corr...